JSP191
Phase 1Small molecule
JSP191 is one of 50 small molecule programs targeting Fanconi Anemia. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Chronic Granulomatous Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Interferon-Gamma
SSPP Pharmaclon Ltd.
Approved
Fludara
SanofiPhase 2
Neoral
NovartisPhase 2
Busulfex
Akero TherapeuticsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Promacta
GSKPhase 2
Actemra
RochePhase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 2
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fanconi Anemia1 trial
Chronic Granulomatous Disease1 trial
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05600907·7 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JSP191. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJasper Therapeutics, Inc.